Brenus Pharma

Brenus Pharma, French Biotech, develops an allogeneic platform to generate First-In-Class tumors antigen-focused immunotherapies; bringing the immune system one step ahead cancer, and changing a paradigm in oncology ! Brenus is targeting resistances to treatments and tumor plasticity resulting in cold tumor indication, which is an important unmet need. Brenus Technology : 🟣Stimulated Tumor Cell (STC) 🟣 Bring together several innovations to educate the immune system to recognize and anticipate cancer relapse targets in the early stages of treatment : a derisked approach with limitless potential. 💡Technology highlights💡 ▪️ Targeting over 200 cancer-related antigens allowing to anticipate mutation of cancer cells and treatment resistances. ▪️ 1st Immunotherapy combining impactful technologies with proven efficacy in 1 product, addressing limits of current treatments. ▪️ A complete off-the shelf approach based on stimulated allogeneic cell lines : allowing cost, timing and supply control and ensuring treatment's availability to a wide population. 🌐Science aspects backed by word class scientific leaders. 🌐First in human clinical study for the lead candidate STC-1010 (mCRC) planed for early 2024 ; with worldwide investigators. ✅CMC expert ✅ ▪️ FDA pre-IND and 2 SA with EU FAMHP (Belgium Agency) done ▪️ Manufacturing readiness ▪️ Efficient and scalable GMP manufacturing process ▪️ Product fully characterized